Tasonermin

Two convergent, systemic mechanisms — TNF-alpha is not directly tubulotoxic at the concentrations that reach the kidney. (1) Hemodynamic/prerenal: when TNF-alpha leaks from the isolated circuit into the systemic circulation it triggers a systemic inflammatory response (SIRS)/septic-shock-like state — a cascade of IL-6/IL-8 and shed soluble TNF receptors, endothelial activation and capillary leak, vasodilation and a fall in systemic vascular resistance (hyperdynamic, distributive shock; notably not primarily nitric-oxide-mediated in human studies). The drop in effective arterial volume and renal perfusion pressure produces prerenal azotemia, and if hypotension is deep or prolonged, ischemic acute tubular necrosis. (2) Pigment/regional: the perfused limb can sustain muscle injury (hyperthermia, ischemia-reperfusion, TNF/melphalan toxicity) causing rhabdomyolysis, myoglobinuria, and compartment syndrome — an ILP-specific route to pigment-cast ('crush kidney') ATN.

When systemic leakage occurs, a septic-shock-like/SIRS picture develops during or immediately after perfusion: fever and chills, tachycardia, high cardiac output with low systemic vascular resistance (distributive/hyperdynamic hypotension), rising cytokines (IL-6/IL-8), and falling urine output with a rising creatinine (prerenal azotemia). Regional/limb effects — pain, marked edema, and in severe cases rhabdomyolysis (high CK, myoglobinuria) and compartment syndrome — provide a second, pigment-mediated route to tubular injury. With negligible leak, patients typically have only fever and chills without renal compromise.

Treat the hemodynamics, not the kidney: aggressive IV crystalloid/colloid resuscitation and vasopressors (noradrenaline) for the TNF-alpha-driven distributive (SIRS/septic-shock-like) hypotension; the resulting prerenal AKI resolves as the circulation is restored and leaked cytokine is cleared. Continue standard ICU support. For rhabdomyolysis-related injury give volume and consider urine alkalinization, and decompress compartment syndrome promptly with fasciotomy to prevent pigment-driven ATN. Established ATN requires supportive care and, rarely, renal replacement therapy. With good leak control, clinically significant renal injury is uncommon.Lesion-level management framework

No renal dose adjustment. Dosing is fixed by limb volume (roughly ~1 mg for arm and up to ~3-4 mg for leg perfusions per protocol/label) and delivered regionally into the isolated circuit, not titrated to systemic eGFR. The relevant safeguard against renal injury is limiting systemic leakage, not renal-function-based dose reduction.

Not clinically relevant. TNF-alpha is a ~17 kDa cytokine cleared by receptor binding and proteolysis with a short systemic half-life (prolonged to a few hours when bound to shed soluble TNF receptors after leakage). It is administered regionally, and dialysis is not used to remove it; renal replacement therapy is reserved for supporting severe AKI/volume overload, not drug clearance.

Distinguish TNF-alpha leak-driven prerenal AKI (hypotension/SIRS during or right after perfusion, brisk response to fluids/pressors, bland sediment) from: (1) rhabdomyolysis/compartment-syndrome pigment ATN (high CK, myoglobinuria, tense painful limb — an ILP-specific cause of acute renal failure); (2) melphalan or other co-administered nephrotoxin effect; (3) surgical hypovolemia/hemorrhage or contrast exposure; (4) true sepsis from wound infection. The temporal link to systemic leakage and the rapid hemodynamic reversibility point to the cytokine-hypotension mechanism.